The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
UNITY BIOTECHNOLOGY, INC. COM 91381U200   2,562,283 1,004,817 SH   SOLE   0 0 1,004,817
DENALI THERAPEUTICS, INC. COM 24823R105   20,472,533 693,749 SH   SOLE   0 0 693,749
SINGULAR GENOMICS SYSTEMS, INC. COM 82933R100   3,153,109 3,798,926 SH   SOLE   0 0 3,798,926
EQRX, INC. COM 26886C107   67,583,798 36,335,375 SH   SOLE   0 0 36,335,375
ERASCA, INC. COM 29479A108   30,513,329 11,055,554 SH   SOLE   0 0 11,055,554
VERVE THERAPEUTICS, INC. COM 92539P101   37,665,169 2,008,809 SH   SOLE   0 0 2,008,809